Psychoactive Assisted Psychotherapy: Are We Ready for Legal MDMA, Psilocybin, Ketamine, and the Psychedelic Medicine Renaissance?
Kate Hawke, MA, Director of the Trauma Transformation Network and Native American Trauma Project, International Energy Psychology Conference Founder. MAPS member since 1986.
FDA Stage 3 clinical trials for MDMA-assisted therapy are now in process with good preliminary results. This is the final stage before anticipated legalization by prescription in approved treatment centers. Psilocybin also received Breakthrough Therapy designation by the FDA and could be available within two years, dramatically changing the therapeutic landscape.
With these advances, we will have new tools to address the roots of depression, anxiety, and traumatic stress at an individual and societal level. At the same time, we must proceed with integrity, research and ethical practices at each step.
Building on Dr. Doblin’s talk, Kate Hawke will discuss how psychedelic therapy is progressing in AZ and as a worldwide movement, and what this might mean for you and the people you care about.
She will cover the following topics:
- Current uses & future plans to integrate these potent medicines into health care systems
- Challenges that mental health professionals will need to navigate once these medicines become legal
- How psychotherapy can be combined with psychoactives for maximum results
- How you can seek help for yourself or your loved ones